The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

被引：49
|
作者：
Pang, Xiaojing [1 ]
Liu, Yang [1 ]
Li, Hua [1 ,2 ]
Chen, Lixia [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Inst Struct Pharmacol & TCM Chem Biol, Coll Pharm, Fuzhou 350122, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 257卷
基金：
中国国家自然科学基金;
关键词：
COVID-19; SARS-CoV-2; M pro inhibitors; Drug repurposing; Drug design; COVALENT INHIBITORS; GENOME SEQUENCE; ACHILLES-HEEL; CORONAVIRUS; DISCOVERY; EBSELEN; IDENTIFICATION; REPLICATION; DESIGN; 3C;
D O I：
10.1016/j.ejmech.2023.115491
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
引用
收藏
页数：20
相关论文
共 50 条
  • [31] Design of novel and highly selective SARS-CoV-2 main protease inhibitors
    Poli, Adi N. R.
    Tietjen, Ian
    Nandwana, Nitesh K.
    Cassel, Joel
    Messick, Troy E.
    Register, Emery T.
    Keeney, Frederick
    Rajaiah, Rajesh
    Verma, Atul K.
    Pandey, Kabita
    Acharya, Arpan
    Byrareddy, Siddappa N.
    Montaner, Luis J.
    Salvino, Joseph M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (10)
  • [32] In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)
    Hernandez-Serda, Manuel Alejandro
    Vazquez-Valadez, Victor H.
    Aguirre-Vidal, Pablo
    Markarian, Nathan M.
    Medina-Franco, Jose L.
    Cardenas-Granados, Luis Alfonso
    Alarcon-Lopez, Aldo Yoshio
    Martinez-Soriano, Pablo A.
    Velazquez-Sanchez, Ana Maria
    Falfan-Valencia, Rodolfo E.
    Angeles, Enrique
    Abrahamyan, Levon
    PATHOGENS, 2024, 13 (10):
  • [33] Molecular Docking Unveils Prospective Inhibitors for the SARS-COV-2 Main Protease
    Ahmad, Fawad
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad Ur
    Khattak, Saeed Ullah
    Butt, Sadia
    Mushtaq, Maryam
    SAINS MALAYSIANA, 2021, 50 (05): : 1473 - 1484
  • [34] In silico assessment of diterpenes as potential inhibitors of SARS-COV-2 main protease
    Abdelrady, Yousef A.
    Ashraf, Naeem Mahmood
    Hamid, Arslan
    Thabet, Hayam S.
    Sayed, Asmaa M.
    Salem, Shimaa H.
    Hassanein, Emad H. M.
    Sayed, Ahmed M.
    FUTURE VIROLOGY, 2023, 18 (05) : 295 - 308
  • [35] Validation of baicalein and oridonin as nonspecific SARS-CoV-2 main protease inhibitors
    Yan, Haohao
    Zhang, Rui
    Yan, Gangan
    Liu, Xiaoping
    Li, Ni
    Chen, Yunyu
    PHYTOTHERAPY RESEARCH, 2024, 38 (03) : 1161 - 1164
  • [36] Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors
    Ullrich, Sven
    Sasi, Vishnu M.
    Mahawaththa, Mithun C.
    Ekanayake, Kasuni B.
    Morewood, Richard
    George, Josemon
    Shuttleworth, Laura
    Zhang, Xiaobai
    Whitefield, Cassidy
    Otting, Gottfried
    Jackson, Colin
    Nitsche, Christoph
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 50
  • [37] Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2
    Paul, Archi Sundar
    Islam, Rajib
    Parves, Md Rimon
    Al Mamun, Abdulla
    Shahriar, Imrul
    Hossain, Md Imran
    Hossain, Md Nayeem
    Ali, Md Ackas
    Halim, Mohammad A.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (04): : 1639 - 1658
  • [38] Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
    Tripathi, Praveen Kumar
    Upadhyay, Saurabh
    Singh, Manju
    Raghavendhar, Siva
    Bhardwaj, Mohit
    Sharma, Pradeep
    Patel, Ashok Kumar
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 164 : 2622 - 2631
  • [39] Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
    Soumya Gulab Katre
    Alpana Jagdish Asnani
    Kumar Pratyush
    Nilima Gangadhar Sakharkar
    Ashwini Gajanan Bhope
    Kanchan Tekram Sawarkar
    Vaibhav Santosh Nimbekar
    Future Journal of Pharmaceutical Sciences, 8
  • [40] Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors
    Fiorucci, Diego
    Milletti, Eva
    Orofino, Francesco
    Brizzi, Antonella
    Mugnaini, Claudia
    Corelli, Federico
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (16): : 6242 - 6248
12345